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Background: Acute intermittent porphyria (AIP) is an autosomal dominant neurovisceral 
inherited disorder due to a defect in the heme biosynthesis pathway. Misdiagnosis of the por-
phyrias is not uncommon.
Case report: We present a case of a 26-year-old female with suspected acute cholecystitis, 
mental status changes, and seizures. Biochemical and molecular investigations confirmed the 
diagnosis of AIP by findings of elevated urinary porphobilinogen, 5-aminolevulinic acid, and 
total porphyrins. DNA molecular testing showed a novel heterozygous mutation (c. 760delC 
p.L254X) in the exon11 of the HMBS gene. To the best of our knowledge, this is the first report 
of a misdiagnosis of AIP presenting with acute cholecystitis.
Conclusion: Clinicians are alerted to consider the possibility of AIP in an adult presenting with 
an acute abdomen, features of cholecystitis, and neuropsychiatric manifestations.
Keywords: porphyria, cholecystitis, acute abdomen, acute intermittent porphyria, HMBS gene, 
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Introduction
Acute intermittent porphyria (AIP) (MIM#176000) is an autosomal dominant inborn 
disorder of heme biosynthesis, that is cause by a mutation in the gene encoding 
hydroxymethylbilane synthase (HMBS) or porphobilinogen deaminase.1 Currently, 
386 mutations are known in HMBS gene, mostly, missense, nonsense, splicing site 
mutations, deletions, insertions, or duplications.2 Because AIP is rare and its clinical 
presentation is heterogeneous, it can be easily misdiagnosed. However, a diagnosis 
of AIP masquerading as acute cholecystitis has not been reported yet in the literature. 
We describe a 26-year-old woman with AIP, misdiagnosed initially as cholecystitis 
and found to have a novel heterozygous mutation in the HMBS gene.
Case report
The Saudi female patient in the UK developed recurrent bouts of abdominal pain, 
nausea, and vomiting during first pregnancy, diagnosed as hyperemesis gravidarum, 
and was treated with IV fluids and antiemetics. There was improvement in the condi-
tion and the patient delivered a healthy child (in Saudi). After 2 months, the patient 
presented with a bout of severe abdominal pain (diagnosed as cholecystitis), followed 
by repeated seizures, hyponatremia, elevated and uncontrolled blood pressure, sinus 
tachycardia, delirium, lower limb weakness, hyporeflexia, and psychological abnor-
malities. She was intubated for 3 days. Initial postextubation, physical examination 
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result was unremarkable except for unexplained behavioral 
disturbances and lower limb weakness. Initial instigations 
showed sodium levels ranged between 118–125 mmol/L 
(135–144 mmol/L), mildly elevated transaminases (aspar-
tate aminotransferase [AST]/alanine transaminase [ALT]), 
and slight elevation of anti-neutrophil antibodies of the 
perinuclear type (P-ANCA). Alkaline phosphatase, biliru-
bin, complete blood count (CBC), thyroid-stimulating hor-
mone (TSH), vitamin B12 level – markers for connective 
tissue diseases, viral titer values, and cerebrospinal fluid 
(CSF) analysis findings were all within normal range. The 
abdominal imaging result was normal, except for contracted 
gallbladder and stones.
Urine became dark red on exposure to light. Total 
porphyrins in urine were elevated: 29,100 nmol/24 hours 
(normal: 214), with main elevation in uroporphyrin 
level, 24,200 nmol/24 hours (normal: 30), and mild 
elevation in coproporphyrin level, 118 nmol/24 hours 
(normal: 38). DNA molecular testing showed a novel 
heterozygous mutation in the exon 11 of the HMBS gene 
(c. 760delC p.L254X). The patient was treated with intra-
venous heme arginate (4 mg/kg/day) for 5 days, that was 
followed by an improvement in the chemical and clinical 
parameters.
Discussion
AIP manifests later in life; only 10% to 15% of those exhibit-
ing carrier types develop the clinical syndrome.3 Typically, 
patients suffer intermittent bouts of neurovisceral attacks for 
up to several days, recurring over several weeks, manifesting 
as severe abdominal pain (95% of cases) and neurological 
and/or psychological symptoms. Abdominal pain is associ-
ated with nausea, vomiting, and constipation. Psychological 
symptoms vary, including mood swings, depression, anxi-
ety, and occasionally, auditory and visual hallucinations, 
disorientation, and mental deterioration.   Neurological 
features can affect the central/peripheral nervous system, 
leading in some cases to seizure, severe myalgia, ascending 
flaccid paralysis and in catastrophic cases to respiratory arrest 
or irreversible quadriplegia. Other commonly encountered 
findings include difficult to treat hypertension, tachycardia 
and SIADH induced hyponatremia. External triggers may be 
porphyrinogenic drugs, alcohol, infections, calorie-restricted 
diet, and stress; internal triggers are hormonal (pregnancy 
and menstrual cycle).2
Diagnosis of AIP is biochemical/molecular dependent. 
Biochemical testing, usually, shows increased concentrations 
of porphobilinogen, 5-aminolevulinic acid, and total por-
phyrins in the urine (mainly uroporphyrins), with decreased 
enzyme activity of porphobilinogen deaminase (50%) in 
erythrocytes. Fecal porphyrin levels are normal or increased. 
Diagnosis of AIP is confirmed by the detection of heterozy-
gous mutation in the HMBS gene.4 In the presented case, the 
pathogenicity of this novel mutation is supported by creation 
of premature stop codon, which is very likely to result in 
truncated protein or loss of protein production.
AIP can be misdiagnosed as psychosis, Guillain–Barré 
syndrome, and chronic hepatitis (Table 1).5–7 The presented 
patient was misdiagnosed as having cholecystitis, as she 
presented with severe abdominal pain and gallbladder stones; 
however, the neuropsychiatric manifestations made the treat-
ing physicians rethink about the diagnosis and treatment. 
To avoid such misdiagnosis in the future, the clinicians 
should consider the possibility of AIP in any individual 
presenting with an acute abdomen and neuropsychiatric 
manifestations.
Attacks of AIP are typically triggered by stress; symptoms 
start during pregnancy. Perhaps, supportive care obfuscated 
manifestations of porphyric attacks. Nonetheless, increased 
estrogen and progesterone levels in pregnancy may precipitate 
Table 1 Misdiagnosis of acute intermittent porphyria
Authors Misdiagnosis Summary of the case
ohtani et al11 Hepatitis 44-year-old female with abdominal pain  
and found to have high transaminases  
1,000 mU/mL
Kumar5 psychosis 15-year-old female diagnosed with  
schizophrenia 1 year ago presented to the  
psychiatric hospital with bizarre behavior of   
2 days’ duration
Cuquemelle et al6 Guillain–Barré syndrome 26-year-old female hospitalized in  
intensive care unit for acute respiratory  
failure associated with an acute  
polyradiculoneuropathyNeuropsychiatric Disease and Treatment
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porphyric attacks. The currently recommended and effective 
treatments in the moderate to severe cases, are the early 
administration of IV human hemin along with glucose load-
ing, discontinuation of triggering porphinogenic drugs, and 
symptomatic treatments of the concomitant hypertension, 
tachycardia, pain and neurological symptoms.
The cause of neuropsychiatric manifestations in AIP is 
not well understood. Several investigators suggested that 
increased levels of hepatic 5-aminolevulinic acid and por-
phobilinogen may play an essential role in the occurrence 
of such complications, and the supportive evidence of such 
theory is the finding that several patients with severe AIP 
became asymptomatic after liver transplantation.8 Other 
postulated mechanisms include focal demyelination, vacu-
olization of the neurons, and multifocal ischemia resulting 
from a vascular narrowing and/or glial proliferation.9 Treat-
ment of such complications consists of prompt intervention 
with the aforementioned supportive measures; in addition, 
gabapentin proves its effectiveness in reducing neuropathic 
pain and seizure episodes.10
Conclusion
AIP could be misdiagnosed as cholecystitis. Our report adds 
a novel nonsense mutation to the previously reported AIP 
mutations.
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